Carsten Niemann

2:02
Monoallelic TP53-mutated CLL patients show durable response to ibrutinib monotherapy
Carsten Niemann
2:04
Understanding risk factors for Ritcher’s transformation: addressing the unmet need
Carsten Niemann
3:33
Death from infection: reducing the risk in patients with CLL
Carsten Niemann
2:21
Promising results from the HOVON-141 trial for CLL
Carsten Niemann
2:01
PHILEMON: a step closer to using MRD to guide treatment decisions in mantle cell lymphoma (MCL)?
Carsten Niemann
2:16
How to treat a previously treated CLL patient
Carsten Niemann
2:31
Use of novel algorithms based on pattern recognition to identify patients in need of CLL treatment
Carsten Niemann
2:03
What we are learning about CLL treatments and the microenvironment
Carsten Niemann
1:13
Guidance on how to prevent infections in patients with CLL
Carsten Niemann
1:44
Upcoming CLL trials on treatment options
Carsten Niemann
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals